1. ALA615435 F Inhibitory activity against Human RhinoVirus serotype-14 3C Protease; NI means No inhibition to 50 uM Human rhinovirus sp. 1 ALA1131817 organism-based format Scientific Literature 2. ALA688246 F Effective concentration in HRV-14 infected H1- HeLa cells by protection assay. Human rhinovirus sp. 18 ALA1131035 organism-based format Scientific Literature 3. ALA880178 F Antirhinoviral activity calculated for mean of fifteen serotypes (HRV-1A, -1B, -2, -6, -14, -15, -21, -22, -25, -30, -41, --50, -67, -86, -89) Human rhinovirus sp. 11 ALA1127423 organism-based format Scientific Literature 4. ALA690578 F Antirhinoviral activity calculated for mean of fifteen serotypes (HRV-1A, -1B, -2, -6, -14, -15, -21, -22, -25, -30, -41, --50, -67, -86, -89); inactive against HRV-1A, -6, -14,-67 Human rhinovirus sp. 3 ALA1127423 organism-based format Scientific Literature 5. ALA690579 F Antirhinoviral activity calculated for mean of fifteen serotypes (HRV-1A, -1B, -2, -6, -14, -15, -21, -22, -25, -30, -41, --50, -67, -86, -89); inactive against HRV-6,-41,-67,-86 Human rhinovirus sp. 1 ALA1127423 organism-based format Scientific Literature 6. ALA690580 F Concentration inhibiting 50% of the serotypes tested to 50% of the viral concentration of untreated controls following 72 hr of exposure Human rhinovirus sp. 21 ALA1128473 organism-based format Scientific Literature 7. ALA690581 F Compound concentration which inhibits 80% of serotypes tested, was reported. Human rhinovirus sp. 4 ALA1128705 organism-based format Scientific Literature 8. ALA691206 F In vitro concentration required to inhibit 80 percent of human rhinovirus 15 serotypes was determined by TCID50 assay Human rhinovirus sp. 33 ALA1127597 organism-based format Scientific Literature 9. ALA691207 F In vitro concentration required to inhibit 80 percent of human rhinovirus 15 serotypes was determined by TCID50 assay;c inactive against majority of serotypes Human rhinovirus sp. 3 ALA1127597 organism-based format Scientific Literature 10. ALA691208 F In vitro concentration required to inhibit 80 percent of human rhinovirus 15 serotypes was determined by TCID50 assay;c= inactive against majority of serotypes Human rhinovirus sp. 3 ALA1127597 organism-based format Scientific Literature 11. ALA691209 F In vitro concentration required to inhibit 80 percent of human rhinovirus 54 serotypes was determined by TCID50 assay Human rhinovirus sp. 6 ALA1127597 organism-based format Scientific Literature 12. ALA691210 F In vitro concentration which inhibits 80% of serotypes tested Human rhinovirus sp. 29 ALA1128705 organism-based format Scientific Literature 13. ALA691211 F In vitro concentration which inhibits 80% of serotypes tested, was reported; not determined Human rhinovirus sp. 1 ALA1128705 organism-based format Scientific Literature 14. ALA691232 F Percent inhibition of 100 HRV strains by the compound at a concentration of 0.064 ug/ml Human rhinovirus sp. 1 ALA1144873 organism-based format Scientific Literature 15. ALA691396 F Minimum inhibitory concentration on HRV serotype 100 Human rhinovirus sp. 2 ALA1128473 organism-based format Scientific Literature 16. ALA857203 F Minimum inhibitory concentration on HRV serotype 11 Human rhinovirus sp. 2 ALA1128473 organism-based format Scientific Literature 17. ALA689402 F Compound was tested in vitro for minimal inhibitory constant against HRV-14; inactive against HRV-1A, -6, -14,-67 Human rhinovirus sp. 1 ALA1127423 organism-based format Scientific Literature 18. ALA689403 F Tested for in vitro antiviral activity against Human rhinovirus (HRV)-14 Human rhinovirus sp. 13 ALA1127423 organism-based format Scientific Literature 19. ALA694488 F Tested for in vitro antiviral activity against Human rhinovirus (HRV)-14; inactive against HRV-1A, -6, -14,-67 Human rhinovirus sp. 1 ALA1127423 organism-based format Scientific Literature 20. ALA694489 F tested for in vitro antiviral activity against Human rhinovirus (HRV)-14 Human rhinovirus sp. 1 ALA1127423 organism-based format Scientific Literature